Sanofi’s Lantus Insulin to Sell for $35 Via GoodRx Site

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma companies.

Under the agreement, GoodRx will sell Lantus supplies at the same price to both insured and uninsured patients, the companies said Thursday. While Sanofi said in March that it would lower list prices for Lantus and cap out-of-pocket costs for people with insurance at $35 a month starting next year, the GoodRx price goes into effect immediately for all customers.

After years of criticism over cost and more ...